Oral drug for mild Alzheimer’s disease symptoms
Part of Brain & nervous system, Mental health clinical trials.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 80 years old
- You have a doctor diagnosis of “probable mild” Alzheimer’s dementia
- In the last 3 months, your thinking test score (MMSE) was between 10 and 26
- In the last 3 months, your Alzheimer’s severity rating (CDR) was 1
- You have no other major cause of dementia and no major recent stroke or brain bleeding
- You must be able to swallow the study capsule and meet basic health/lab safety checks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
This study tests a sequence of treatments to see if they can help people with Alzheimer's disease or mild cognitive impairment. It aims to slow down memory decline and improve daily function.
This study tests an oral medication that may change how the body processes energy to help people with early Alzheimer's disease. It aims to see if the treatment can slow down memory loss and improve daily function.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.